Patents Assigned to Merck
  • Potassium channel inhibitors
    Patent number: 7879839
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Douglas C. Beshore, B. Wesley Trotter, Kausik K. Nanda, Richard Isaacs, Linda S. Payne, Lou Anne Neilson, Zhicai Wu, Mark T. Bilodeau, Peter J. Manley, Adrienne E. Balitza
  • Thiazole derivatives and use thereof
    Patent number: 7879888
    Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: February 1, 2011
    Assignee: Merck Serono SA
    Inventors: Anna Quattropani, David Covini, Vincent Pomel, Jerome Dorbais, Thomas Rueckle
  • LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY
    Publication number: 20110019119
    Abstract: The instant invention relates to dielectrically positive nematic media comprising one, two or more compounds of formula I one or more compounds selected from the group of formulae II and III and one or more compounds selected from the group of formulae IV and V wherein the parameters are as defined in claim 1 with the proviso that the media comprise one or more compounds of formula III, wherein n and o both are 1 and all rings are 1,4-phenylene, which independently of each other optionally are fluorinated once or twice, and/or one or more compounds of formula V, wherein q is 2, as well as to liquid crystal displays comprising these media, especially to TN-displays and in particular to active matrix displays.
    Type: Application
    Filed: March 11, 2009
    Publication date: January 27, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin (Kelun) Shu, Carol (Yi-Hsuan) Lin, Fred (Jer-Lin) Chen, Mark Verrall
  • MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
    Publication number: 20110021516
    Abstract: The present invention is directed to compounds of the formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Application
    Filed: March 24, 2009
    Publication date: January 27, 2011
    Applicant: MERCK SHARP & DOHME CORP
    Inventors: Harold G. Selnick, Ian M. Bell, Melody McWherter, Donnette D. Staas, Shawn J. Stachel, Thomas Steele, Craig Stump, Michael R. Wood, C. Blair Zartman
  • COMPOSITION FOR MANUFACTURING SIO2 RESIST LAYERS AND METHOD OF ITS USE
    Publication number: 20110021037
    Abstract: The present invention relates to compositions, which are useful for the generation of patterned or structured SiO2-layers or of SiO2-lines during the manufacturing process of semiconductor devices, and which are suitable for the application in inkjet operations. The present invention also relates to a modified process of manufacturing semiconductor devices taking advantage of these new compositions.
    Type: Application
    Filed: March 2, 2009
    Publication date: January 27, 2011
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Werner Stockum, Ingo Koehler, Arjan Meijer, Paul Craig Brookes, Katie Patterson, Mark James
  • 1-acyldihydropyrazole derivatives
    Patent number: 7875644
    Abstract: Compounds of the formula (I), in which R1, R2, R3a, R3b, R3c and R3d have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: January 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Andree Blaukat
  • Phthalazinones
    Patent number: 7875614
    Abstract: Compounds of the formula I, in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: January 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Kai Schiemann, Ulrich Emde, Frank Zenke, Christiane Amendt
  • Pyridyl amide T-type calcium channel antagonists
    Patent number: 7875636
    Abstract: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: January 25, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James C. Barrow, Thomas S. Reger, Zhi-Qiang Yang
  • Crystalline forms of an inhibitor of 11-?-hydroxysteroid dehydrogenase type 1
    Patent number: 7875642
    Abstract: Novel crystalline salts of 3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole are potent inhibitors of 11?-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: January 25, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yuri Bereznitski, Mark A. Huffman, Joseph E. Lynch, Matthew Zhao
  • Effect pigments that are surface-modified with LCST and/or UCST polymers
    Patent number: 7875112
    Abstract: The present invention relates to surface-modified effect pigments based on flake-form substrates which are distinguished by the fact that they are sheathed with one or more layers of immobilised LCST and/or UCST polymers. The invention furthermore relates to a process for the production of the surface-modified effect pigments and to the use thereof in surface coatings, water-borne coatings, powder coatings, paints, printing inks, security printing inks, plastics, concrete, in cosmetic formulations, in agricultural sheeting and tarpaulins, for the laser marking of papers and plastics, as light protection, as pigment for corrosion protection and for the preparation of pigment compositions and dry preparations.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: January 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Adalbert Huber, Marc Entenmann, Thadeus Schauer
  • Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Publication number: 20110015194
    Abstract: The present invention relates to quinoxalinone derivatives of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Application
    Filed: January 15, 2009
    Publication date: January 20, 2011
    Applicant: Merck Patent Gesellschaft
    Inventors: Gérard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
  • Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Publication number: 20110015210
    Abstract: The present invention relates to pyrazinone derivatives of formula (I), wherein n, R1, R2, R3 and R4 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Application
    Filed: January 15, 2009
    Publication date: January 20, 2011
    Applicant: MERCK PAATENT GESELLSCHAFT
    Inventors: Gérard Botton, Micheline Kergoat, Christine Charon, Samer Elbawab
  • METAL COMPLEXES
    Publication number: 20110012100
    Abstract: The present invention relates to metal complexes of the formula (1) and to the use thereof in organic electroluminescent devices, and to organic electroluminescent devices which comprise these metal complexes.
    Type: Application
    Filed: March 4, 2009
    Publication date: January 20, 2011
    Applicant: Merck Patent GmbH
    Inventor: Philipp Stoessel
  • Illuminated Tile
    Publication number: 20110013390
    Abstract: The present invention relates to a light-emitting tile having a layer structure which includes a visible plate (2) and at least one illuminant, which is characterised in that the illuminant provided is at least one OLED (3).
    Type: Application
    Filed: March 20, 2007
    Publication date: January 20, 2011
    Applicant: Merck Patent GmbH Patents & Scientific Information
    Inventors: Alexander Biebel, Thomas Meisel
  • PTPH1 Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20110015254
    Abstract: The present invention relates to the use of PTPH1 inhibitors in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. The present invention also relates to a method of identifying compounds useful in the prevention or treatment of Alzheimer's Disease, or a symptom thereof.
    Type: Application
    Filed: March 17, 2009
    Publication date: January 20, 2011
    Applicant: MERCK SERONO SA
    Inventors: Claudia Patrignani, Valeria Muzio, Maria-Chiara Magnone, Paola Zaratin, Beatrice Greco
  • OPTOELECTRONIC COMPONENT COMPRISING NEUTRAL TRANSITION METAL COMPLEXES
    Publication number: 20110012099
    Abstract: The invention relates to the use of compositions as emitters or absorbers in an electronic component, wherein the compositions have a first neutral transition metal complex and a second neutral transition metal complex. According to the invention, the first transition metal complex and the second transition metal complex together form a column structure. The invention further relates to a method for the production of electronic components having such compositions.
    Type: Application
    Filed: February 25, 2009
    Publication date: January 20, 2011
    Applicant: Merck Patent GmbH
    Inventors: Hartmut Yersin, Tobias Fischer, Rafal Czerwieniec, Uwe Monkowius
  • Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
    Patent number: 7872024
    Abstract: The present invention relates to a novel class of hydroxamic acid derivatives carbamate, urea, amide and sulfonamide substitutions. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: January 18, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joey Methot, Thomas A. Miller, David J. Witter
  • 3-aminoindazoles
    Patent number: 7872039
    Abstract: Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: January 18, 2011
    Assignee: Merck Patent Gesellschaft
    Inventors: Dieter Dorsch, Lars Thore Burgdorf, Rolf Gericke, Norbert Beier, Werner Mederski, Florian Lang
  • CSF3R polypeptides and uses thereof
    Patent number: 7871979
    Abstract: The present invention relates to CSF3R polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: January 18, 2011
    Assignee: Merck Serono SA
    Inventors: Melanie Yorke-Smith, Andreas Pigni
  • Interleukin-12p40 variants with improved stability
    Patent number: 7872107
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: January 18, 2011
    Assignee: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo, Pascal André Stein